Table 1.
Compounds | IC50 (nM) | Ratio of BuChE/AChE IC50 | Multi-targeted ligand | Ref | |
AChE | BuChE | ||||
Tacrine | 174.00 | 32.00 | 5.40 | — | [151] |
5 | 150.00 | 36.00 | 0.24 | BACE1 inhibition, Neuroprotection against glutamate toxicity | [145] |
6 | 49.00 | 93280.00 | 1903.67 | Neuroprotection and Aβ aggregation inhibitory activities | [146] |
7 | 3.90 | 24.30 | 6.23 | Inhibition of Aβ 42 self-aggregation and fibril formation, Antioxidant activity, Neuroprotection | [147] |
8a | 580.00 | >66050 | >113.88 | — | [148] |
8b | 440.00 | >61020 | >138.68 | — | |
9 | 3050.00 | 3190.00 | 1.05 | Moderate-to-potent calcium channel blockers | [149] |
10 | 2.20 | 4.93 | 2.24 | — | [150] |
11 | 0.12 | 361.52 | 3012.67 | HDAC inhibition, Cu2+ chelating properties | [151] |
12 | 26.00 | 9.00 | 0.35 | — | [152] |
13 | 259.00 | – | – | Antioxidant activity | [141] |
14 | 22.15 | 6.96 | 0.31 | — | [142] |
15 | 10.00 | 57.00 | 5.70 | Antioxidant activity | [143] |
16a | 13.00 | 21.00 | 1.62 | — | [144] |
16b | 2.00 | 110.00 | 55.00 | — | |
17 | 33.40 | 62.00 | 1.86 | NMDA receptors inhibition | [153] |